News coverage about Globus Medical (NYSE:GMED) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Globus Medical earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.4165484302346 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

A number of equities analysts have issued reports on the stock. Barclays PLC reissued an “underweight” rating and set a $28.00 price target (down from $30.00) on shares of Globus Medical in a research report on Wednesday. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Gabelli reissued a “buy” rating on shares of Globus Medical in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $35.00 price target on shares of Globus Medical and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Finally, BidaskClub lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $30.43.

Globus Medical (GMED) traded up 1.81% during trading on Friday, hitting $29.30. 610,322 shares of the stock traded hands. Globus Medical has a 12 month low of $19.25 and a 12 month high of $34.03. The firm’s 50-day moving average is $31.79 and its 200-day moving average is $30.14. The stock has a market cap of $2.82 billion, a P/E ratio of 26.40 and a beta of 0.60.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.02. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The firm had revenue of $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. During the same period last year, the company earned $0.29 earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts forecast that Globus Medical will post $1.27 EPS for the current year.

In related news, President Anthony L. Williams sold 16,153 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $31.94, for a total transaction of $515,926.82. Following the completion of the sale, the president now directly owns 16,153 shares of the company’s stock, valued at $515,926.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 28.21% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Globus Medical (GMED) Earns Coverage Optimism Score of 0.18” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/globus-medical-gmed-earns-coverage-optimism-score-of-0-18/1478389.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.